검색결과 : 228건
| No. | Article |
|---|---|
| 1 |
beta-TrCP1-variant 4, a novel splice variant of beta-TrCP1, is a negative regulator of beta-TrCP1-variant 1 in beta-catenin degradation Lee EJ, Cho M, Rho SB, Park J, Chae DA, Nguyen QTT Biochemical and Biophysical Research Communications, 542, 9, 2021 |
| 2 |
LSR promotes epithelial ovarian cancer cell survival under energy stress through the LKB1-AMPK pathway Takahashi Y, Serada S, Ohkawara T, Fujimoto M, Hiramatsu K, Ueda Y, Kimura T, Takemori H, Naka T Biochemical and Biophysical Research Communications, 537, 93, 2021 |
| 3 |
Immunotherapeutic strategies for the treatment of ovarian cancer: current status and future direction Duwa R, Jeong JH, Yook SM Journal of Industrial and Engineering Chemistry, 94, 62, 2021 |
| 4 |
NCK1-AS1 promotes NCK1 expression to facilitate tumorigenesis and chemo-resistance in ovarian cancer Chang H, Li BX, Zhang X, Meng XK Biochemical and Biophysical Research Communications, 522(2), 292, 2020 |
| 5 |
TGF-beta 1 fucosylation enhances the autophagy and mitophagy via PI3K/Akt and Ras-Raf-MEK-ERK in ovarian carcinoma Jin S, Gao J, Qi Y, Hao YY, Li X, Liu Q, Liu JJ, Liu DW, Zhu LC, Lin B Biochemical and Biophysical Research Communications, 524(4), 970, 2020 |
| 6 |
Ubiquitin-specific protease 14 regulates ovarian cancer cisplatin-resistance by stabilizing BCL6 oncoprotein Shen J, Hong L, Chen L Biochemical and Biophysical Research Communications, 524(3), 683, 2020 |
| 7 |
Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer Cao BH, Liu MT, Wang L, Liang BX, Feng YF, Chen XP, Shi YY, Zhang JL, Ye XD, Tian Y, Zhi C, Li JP, Lian H, Wu QD, Zhang ZF Biochemical and Biophysical Research Communications, 524(1), 96, 2020 |
| 8 |
Depletion of UBE2C reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1 Li JJ, Zhi XL, Shen XQ, Chen C, Yuan L, Dong XH, Zhu CQ, Yao LQ, Chen M Biochemical and Biophysical Research Communications, 523(2), 434, 2020 |
| 9 |
beta-TRCP-mediated AEBP2 ubiquitination and destruction controls cisplatin resistance in ovarian cancer Zhang Q, Wang W, Gao Q Biochemical and Biophysical Research Communications, 523(1), 274, 2020 |
| 10 |
Exploring the potential of engineered exosomes as delivery systems for tumor-suppressor microRNA replacement therapy in ovarian cancer Kobayashi M, Sawada K, Miyamoto M, Shimizu A, Yamamoto M, Kinose Y, Nakamura K, Kawano M, Kodama M, Hashimoto K, Kimura T Biochemical and Biophysical Research Communications, 527(1), 153, 2020 |